Loading company
ENDRA Life Sciences Inc.
NDRA · Nasdaq · Healthcare · Diagnostics and Research
$5.93-1.9%Sep 28 close
- 1M
- +18.4%
- 6M
- +26.6%
- 1Y
- +10.1%
- 5Y
- -100.0%
NDRA · Nasdaq · Healthcare · Diagnostics and Research
$5.93-1.9%Sep 28 close
The quarter ending December 31, 2019, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2019 | 3 months toDec 31, 2018 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | $159.9K | -$1.2M | +113.05% |
| Profit per share | $0.06 | -$0.08 | +175.00% |
| Free Cash Flow | -$1.6M | -$1.5M | -6.33% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
ENDRA Life Sciences Inc. has no earnings call transcript available.
“During the second quarter, we achieved an important objective for ENDRA and its stockholders by entering into a definitive merger agreement with Noble Africa following our strategic alternatives process,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS® is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. Our press releases and financial and other material information are routinely posted to and accessible on the Investors section of our website, www.endrainc.com.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from ENDRA Life Sciences Inc.’s Item 2.02 8-K filed August 17, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.